David Collingridge, Editor-in-Chief at The Lancet Oncology, shared on LinkedIn:
“Every year, journals around the world receive different metrics to reflect their performance. While only a limited measure of our impact, I am pleased to share that The Lancet Oncology has an Impact Factor of 35·9 and a Scopus CiteScore of 50·8.
Congratulations to our authors and peer reviewers, whose expertise and hard work enable us to continuously publish some of the best science for better lives.
You can access our full reach and impact statement, including additional measures of our global reach and high impact, here.”
More Posts Featuring The Lancet Oncology.